Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
NCT07545213Phase 2Not yet recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2026
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan, anlotinib in non-small cell lung cancer (NSCLC), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecananlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07545213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545213.